2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(5-methoxy-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]phenyl]- manufacturers
- BEBT-109
-
- $459.00
-
2026-07-27
- CAS:2050906-40-4
- Purity: 97.26%
- Supply Ability: 10g
|
| | 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(5-methoxy-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]phenyl]- Basic information |
| | 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(5-methoxy-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]phenyl]- Chemical Properties |
| density | 1.24±0.1 g/cm3(Predicted) | | form | Solid | | pka | 12.65±0.70(Predicted) | | color | White to off-white |
| | 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(5-methoxy-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]phenyl]- Usage And Synthesis |
| Uses | BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research[1]. | | References | [1] Fan F, et al BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Transl Oncol. 2021 Feb;14(2):100961. DOI:10.1016/j.tranon.2020.100961 |
| | 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(5-methoxy-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]phenyl]- Preparation Products And Raw materials |
|